消息面上，据央广网消息，当前正值流感等呼吸道传染病高发季节，奥司他韦、玛巴洛沙韦等流感药物 的需求量不断增加。数据显示，奥司他韦近七天销量增长率达237%，玛巴洛沙韦上涨达180%。公开资 料显示，东阳光药有着"流感药物之王"称号，旗下的流感药物奥司他韦(商品名：可威)长期占据着国内 主要市场份额。 此外，11月25日晚，东阳光药发布公告称，公司有意于公开市场上购回自身股份。公司管理层对集团前 景充满信心，而建议回购体现了董事会及管理层团队对公司长远业务前景及发展的信心。董事会认为建 议回购符合公司与公司股东的整体最佳利益。 东阳光（600673）药(06887)早盘涨超4%，截至发稿，涨3.43%，报45.88港元，成交额454.31万港元。 ...

消息面上，据央广网消息，当前正值流感等呼吸道传染病高发季节，奥司他韦、玛巴洛沙韦等流感药物 的需求量不断增加。数据显示，奥司他韦近七天销量增长率达237%，玛巴洛沙韦上涨达180%。公开资 料显示，东阳光药有着"流感药物之王"称号，旗下的流感药物奥司他韦（商品名：可威）长期占据着国 内主要市场份额。 智通财经APP获悉，东阳光药(06887)早盘涨超4%，截至发稿，涨3.43%，报45.88港元，成交额454.31万 港元。 此外，11月25日晚，东阳光药发布公告称，公司有意于公开市场上购回自身股份。公司管理层对集团前 景充满信心，而建议回购体现了董事会及管理层团队对公司长远业务前景及发展的信心。董事会认为建 议回购符合公司与公司股东的整体最佳利益。 ...

智通财经APP讯，东阳光药(06887)发布公告，公司有意于公开市场上购回自身股份。公司管理层对集团 前景充满信心，而建议回购体现了董事会及管理层团队对公司长远业务前景及发展的信心。董事会认为 建议回购符合公司与公司股东的整体最佳利益。 ...

格隆汇11月25日丨东阳光药(06887.HK)公告，公司有意于公开市场上购回自身股份。公司管理层对集团 前景充满信心，而建议回购体现了董事会及管理层团队对公司长远业务前景及发展的信心。董事会认为 建议回购符合公司与公司股东整体最佳利益。 ...

（股份代號：6887） 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） 承董事會命 廣東東陽光藥業股份有限公司 董事長 張英俊博士 中國，東莞 自願公告 有意購回股份 本公告由廣東東陽光藥業股份有限公司（「本公司」）自願刊發。 本公司董事（「董事」）會（「董事會」）謹此宣佈，本公司有意於公開市場上購回（「建 議回購」）自身股份（「股份」）。本公司管理層對本集團前景充滿信心，而建議回購 體現了董事會及管理層團隊對本公司長遠業務前景及發展的信心。董事會認為建 議回購符合本公司與本公司股東（「股東」）之整體最佳利益。 截至本公告日期，本公司尚未根據《香港聯合交易所有限公司證券上市規則》（「上 市 規 則 」）第 10.06 條 獲 得 ...

Core Viewpoint - The demand for flu medications has surged as the country enters the flu season, leading to potential supply shortages and price volatility in the market [1] Group 1: Company Supply Chain and Market Strategy - Dongyang Sunshine Pharmaceutical, a major supplier of Oseltamivir, has established a mature and comprehensive supply chain system and emergency response plan to ensure stable drug supply during peak flu seasons [1] - The company has achieved full coverage of core terminals, including hospitals, chain pharmacies, and online platforms, while maintaining sufficient terminal inventory [1] - During the flu peak season, the company plans to collaborate with industry partners to meet medication needs across various market levels, providing stable and reliable drug support for public health [1] Group 2: Future Innovations and Strategic Goals - The company aims to leverage its R&D platform and strengths in the anti-infection field to innovate in flu treatment, utilizing AI pharmaceutical technology to accelerate the development of new products [1] - New pipeline products are expected to create synergies with Oseltamivir, enriching the pediatric anti-infection product lineup [1] - The company targets a strategic goal of reaching a scale of 10 billion in the anti-infection pediatric segment over the next 3-5 years, reinforcing its core competitiveness in flu treatment [1]

Group 1 - The core viewpoint of the article highlights the significant increase in sales of flu medications, particularly Oseltamivir and Baloxavir, amid rising flu activity across multiple regions in China [1] - Dongyangguang Pharmaceutical (06887) experienced a stock price increase of over 4%, reaching HKD 44.12, with a trading volume of HKD 11.73 million [1] - The sales growth rate for Oseltamivir over the past week was reported at 237%, while Baloxavir saw an increase of 180% [1] Group 2 - Dongyangguang Pharmaceutical is recognized as the "king of flu medications," with its Oseltamivir (brand name: Kewai) holding a significant market share in China, particularly in the pediatric segment [1] - The overall sales revenue for Dongyangguang Pharmaceutical is projected to reach CNY 1.301 billion in the first half of 2025 [1]

Core Viewpoint - Dongyangguang Pharmaceutical (600673) has seen a significant stock price increase of over 4%, attributed to rising flu activity across multiple regions in China, leading to increased sales of flu medications like Oseltamivir and Baloxavir [1] Company Summary - Dongyangguang Pharmaceutical's stock rose by 4.65%, reaching HKD 44.12, with a trading volume of HKD 11.7372 million [1] - The company is recognized as the "King of Flu Medications," with its Oseltamivir (brand name: Kewai) holding a dominant market share in China, particularly in the pediatric segment [1] - Projected sales for the first half of 2025 are expected to reach CNY 1.301 billion [1] Industry Summary - Recent data indicates a notable increase in the sales of flu medications, with Oseltamivir's sales growth rate reaching 237% over the past week, and Baloxavir's sales increasing by 180% [1] - There has been a general uptick in sales for cold, fever-reducing, detoxifying, cough-relieving, and nasal spray medications [1]

Summary of Key Points Core Viewpoint - As of November 21, 14 stocks reached their 52-week highs, with Hengfa Optical (01134), Chaowei Holdings (08059), and Cassava Resources (00841) leading the gains at 42.11%, 30.56%, and 22.49% respectively [1]. 52-Week Highs - Hengfa Optical (01134) closed at 0.375, with a peak price of 0.540, marking a 42.11% increase [1]. - Chaowei Holdings (08059) closed at 0.030, reaching a high of 0.047, reflecting a 30.56% rise [1]. - Cassava Resources (00841) closed at 0.200, with a maximum price of 0.207, indicating a 22.49% increase [1]. - Other notable stocks include Sibor Systems (08319) at 15.04%, MOS HOUSE (01653) at 11.46%, and Tianjin Jianfa (02515) at 5.19% [1]. 52-Week Lows - China Pengfei Group (03348) reached a low of 1.100, down 20.09% from its peak [1]. - China Information Technology (08178) closed at 0.285, reflecting a 19.35% decrease [1]. - XL Ernan Strategy - U (09799) saw a decline of 14.27% [1]. - Other significant declines include Hesai - W (02525) at -10.54% and MBC Bitcoin - U (03425) at -9.09% [1]. Additional Notable Stocks - Stocks like MBC Bitcoin (03430) and Tongyuan Kang Pharmaceutical - B (02410) also experienced declines of 6.64% and 6.62% respectively [2]. - The overall trend indicates a mix of significant gains in certain stocks while others are facing substantial losses, reflecting a volatile market environment [1][2].

Market Overview - The Hang Seng Index rose by 0.61%, gaining 161 points to close at 26,406 points, while the Hang Seng Tech Index increased by 0.12%. The morning trading volume in Hong Kong reached 114.1 billion HKD [1]. Company Highlights - China Duty Free Group (601888) (01880) saw a surge of over 13% as the new duty-free policy in Hainan shows positive effects, with institutions suggesting a potential industry turning point [1]. - Pop Mart (09992) increased by over 6% due to gradual capacity expansion, with management expecting stronger sales performance in Q4 [1]. - Dongyang Sunshine Pharmaceutical (600673) (06887) rose by over 4% as flu activity is on the rise, and institutions are optimistic about the company's innovative pipeline development [1]. - China Liansu (02128) gained over 5% as the company is expected to benefit significantly from urban pipeline upgrades under the 14th Five-Year Plan [1]. - Hou Shang Ayi (02589) increased by over 8% after the company proposed adopting an H-share incentive plan, successfully entering the "10,000-store club" [1]. - Education stocks performed well, with institutions noting overall good performance in the education sector and the potential for AI+ education to enhance valuation. China Education Holdings (00839) rose by 8%, Thinking Academy (01769) by 3.3%, and New Oriental-S (09901) by 3.25% [1]. - Ruipu Lanjun (00666) increased by over 6% as global demand for energy storage remains strong, with the company reporting over 50 GWh of energy storage battery shipments in the first three quarters [1]. - Gilead Sciences-B (01672) rose by over 6% after being included in the MSCI Global Small Cap Index, with significant weight loss effects from ASC30 [1]. - Goldwind Technology (002202) (02208) fell by over 5% as a major shareholder, Harmony Health, plans to further reduce its stake by up to 1%, following a previous reduction at the end of last month [1]. - Robotics concept stocks declined, with DCH Holdings (00179) dropping over 4% and Sanhua Intelligent Controls (002050) (02050) falling over 3% [1].